{"id":6996,"date":"2026-04-01T11:17:07","date_gmt":"2026-04-01T09:17:07","guid":{"rendered":"https:\/\/mediconomics.com\/?post_type=glossary&#038;p=6996"},"modified":"2026-07-13T19:09:49","modified_gmt":"2026-07-13T17:09:49","slug":"econsent-electronic-consent","status":"publish","type":"glossary","link":"https:\/\/mediconomics.com\/en\/glossar\/econsent-electronic-consent\/","title":{"rendered":"eConsent (Electronic Consent)"},"content":{"rendered":"<p>Electronic Consent (eConsent) refers to the use of digital and interactive technologies to conduct the consent process in clinical trials. Instead of the classic paper-based Informed Consent Form, information about the trial is conveyed in digital form \u2013 for example via tablet, smartphone app, web portal or video \u2013 and consent is obtained electronically and documented in full. eConsent is not a replacement for the personal explanatory discussion with the investigator, but a complementary tool for improving comprehension, traceability and participant experience. In decentralised clinical trials \u2013 so-called Decentralized Clinical Trials \u2013 eConsent is often a basic prerequisite for geographically independent participation, in which trial participants do not necessarily need to appear physically at the investigational site.<\/p>\n<h2>Regulatory basis in the EU<\/h2>\n<p>eConsent solutions must meet the same regulatory requirements as paper-based consent documents. In the EU, Regulation (EU) 536\/2014 (Clinical Trial Regulation, CTR) expressly permits electronic consent procedures, provided that Member States allow this and suitable methods are used to ensure authenticity and traceability. The ICH E6(R3) GCP guideline addresses eConsent as part of decentralised and hybrid trial designs and stipulates that the electronic system must protect the rights, safety and wellbeing of participants at least to the same extent as paper-based procedures. The eIDAS Regulation (910\/2014) applies to electronic signatures in the EU; a qualified electronic signature is legally equivalent to a handwritten signature. As the concrete implementation varies considerably at Member State level, a country-specific regulatory review before trial start is essential \u2013 some EU countries still require an initial in-person discussion at the investigational site before consent may be obtained electronically.<\/p>\n<h2>Advantages over paper-based procedures<\/h2>\n<p>Compared with the classic paper-based procedure, eConsent offers several key advantages in clinical research:<\/p>\n<ul>\n<li><strong>Improved participant understanding:<\/strong> multimedia content such as videos, animations and interactive quiz elements significantly ease the understanding of complex medical information.<\/li>\n<li><strong>Increased accessibility:<\/strong> participants can access study information in their own language and at their own pace \u2013 including from home (remote eConsent).<\/li>\n<li><strong>Complete documentation:<\/strong> the system automatically logs which sections were read, for how long, and whether all mandatory questions were answered correctly.<\/li>\n<li><strong>Simplified amendment processes:<\/strong> updates following a protocol amendment can be communicated centrally and quickly to all active participants; the re-consent process is documented entirely digitally and in a revision-secure manner.<\/li>\n<li><strong>Reduced burden at the investigational site:<\/strong> less paper logistics, fewer errors due to missing signatures or incomplete date fields, and fewer administrative in-person appointments for participants.<\/li>\n<\/ul>\n<p>Remote eConsent also enables geographically independent participant recruitment. Trials using this procedure benefit from a potentially broader and more diverse study population. For participants with limited mobility or chronic conditions, purely administrative visits to the investigational site are eliminated \u2013 which can promote compliance and willingness to participate throughout the trial.<\/p>\n<h2>Technical requirements for eConsent platforms<\/h2>\n<p>eConsent platforms must be operated as validated computer systems insofar as they generate GCP-relevant data. The requirements of EU GMP Annex 11 also apply by analogy to GCP systems. In concrete terms, this means: a complete audit trail with timestamp and user identification, role-based access controls, data encryption, validation documentation (IQ\/OQ\/PQ) and disaster recovery concepts. The data must be legible, complete and correctly retrievable at all times, in accordance with the ALCOA principles (Attributable, Legible, Contemporaneous, Original, Accurate). In addition, the platform must be accessible, user-friendly and available in all required study languages to include a diverse and international participant population.<\/p>\n<h2>Significance for clinical trials<\/h2>\n<p>eConsent is increasingly becoming the standard in patient-centric and decentralised trial designs. The EMA and FDA have published guidance documents on eConsent and Decentralized Clinical Trials, demonstrating growing regulatory acceptance. At the same time, the core principles of informed consent remain unchanged: voluntariness, comprehensibility and complete information for the trial participant. The decision on the suitability of eConsent for a specific trial must take into account the patient population, the trial indication and country-specific requirements. Full-service CROs such as mediconomics support sponsors in selecting suitable platforms, country-specific regulatory assessment, and technical integration into Electronic Data Capture, Clinical Trial Management Systems and the Trial Master File.<\/p>\n<h2>Frequently Asked Questions (FAQ)<\/h2>\n<p><strong>Is eConsent permitted in all EU countries?<\/strong><\/p>\n<p>Regulation (EU) 536\/2014 permits eConsent in principle but leaves the specific arrangements to Member States. In practice, there are considerable differences: while some countries fully accept remote eConsent, others require an initial in-person discussion at the investigational site. A country-specific regulatory review is therefore required for each participating country before trial start. The EMA has published a reflection paper on this topic (EMA\/321925\/2021).<\/p>\n<p><strong>What technical requirements must an eConsent platform meet?<\/strong><\/p>\n<p>eConsent systems must be operated as validated computer systems. Mandatory requirements include: a complete audit trail, role-based access controls, electronic signature in accordance with eIDAS or 21 CFR Part 11, data encryption, backup and recovery processes, and complete validation documentation. The platform must be accessible and available in the required languages.<\/p>\n<p><strong>How is eConsent handled in the case of a protocol amendment?<\/strong><\/p>\n<p>Following approval of an amendment by the ethics committee, the updated consent version is stored centrally on the platform. Affected participants receive an automated notification, must confirm the revised sections and sign again (re-consent). The system automatically documents which participant signed which version at which point in time \u2013 a clear advantage over paper-based processes, in which tracking is manual and more error-prone.<\/p>\n<h2>Regulatory references<\/h2>\n<ul>\n<li>Regulation (EU) 536\/2014 (CTR), Art. 29: informed consent, electronic means<\/li>\n<li>ICH E6(R3) GCP guideline: Informed Consent, Electronic Systems<\/li>\n<li>EMA Reflection Paper on eConsent (EMA\/321925\/2021)<\/li>\n<li>Regulation (EU) 910\/2014 (eIDAS): electronic signatures and trust services<\/li>\n<li>Regulation (EU) 2016\/679 (GDPR): data protection requirements for personal health data<\/li>\n<li>FDA Guidance: Use of Electronic Informed Consent (2016)<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Electronic Consent (eConsent) refers to the use of digital and interactive technologies to conduct the consent process in clinical trials. Instead of the classic paper-based Informed Consent Form, information about the trial is conveyed in digital form \u2013 for example via tablet, smartphone app, web portal or video \u2013 and consent is obtained electronically and [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6996","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6996\/revisions"}],"predecessor-version":[{"id":6999,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6996\/revisions\/6999"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6996"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}